Victoria P. Werth, ACR 2022: Findings from the phase 2 LILAC study of BIIB059 in cutaneous lupus erythematosus

Part B of the phase 2 LILAC study (NCT02847598) investigated BIIB059, a humanized monoclonal antibody against BDCA2, for the treatment of cutaneous lupus erythematosus (CLE). In this touchIMMUNOLOGY interview, we were delighted to speak with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) around the unmet needs in the treatment of CLE, the rationale for investigating BIIB059 in this indication, and the findings from the analysis presented at ACR.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract ‘Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participants with Cutaneous Lupus Erythematosus (CLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part B).’ (Abstract number: 0365) was presented at the ACR Convergence, November 10–14, 2022.

Questions

1. Could you tell us a little about cutaneous lupus erythematosus (CLE) and the unmet needs in its treatment? (0:16)
2. What is BIIB059 and what is the rationale for its use in the treatment of CLE? (3:04)
3. What did the LILAC study teach us about the efficacy and safety of BIIB059 in this indication? (4:22)
4. What additional efficacy outcomes are described in this presentation? (5:04)
5. What will be the next steps in the clinical development of BIIB059? (7:07)

Disclosures: Victoria P. Werth discloses receiving grants from: Celgene, Amgen, Janssen, Biogen, Gilead, Viela, Horizon therapeutics, and Ventus; consulting for: Astra-Zeneca, Pfizer, Biogen, Celgene, Resolve, Janssen, Gilead, Lilly, BMS, Nektar, Abbvie, Viela, GSK, EMD Serona, Sanofi, Anaptysbio, Amgen, Merck Kyowa Kirin, Rome Therapeutics, and Xencor; serving on advisory boards for: Lupus Foundation of America; and receiving honorarium from: Astra-Zeneca, Pfizer, Biogen, Celgene, Resolve, Janssen, Gilead, Lilly, BMS, Nektar, Abbvie, Viela, GSK, EMD Serona, Sanofi, Anaptysbio, Amgen, Merck Kyowa Kirin, Rome Therapeutics, and Xencor.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the ACR Convergence 2022.